Table 3.

Dactylitis at week 24 (LOCF) and weeks 52, 104 and 156 (as observed)*

Dactylitis count†	Week 24			Week 52		Week 104		Week 156
	Placebo (n=194)	Apremilast		Apremilast		Apremilast		Apremilast
		30 mg two times per day (n=214)	20 mg two times per day (n=202)	30 mg two times per day (n=249)	20 mg two times per day (n=225)	30 mg t two times per day (n=200)	20 mg two times per day (n=182)	30 mg two times per day (n=181)	20 mg two times per day (n=157)
Baseline, mean	3.3	3.2	3.4	3.4	3.3	3.4	3.2	3.4	3.0
Mean change from baseline	−1.3	−1.8‡	−1.6	−2.5	−2.3	−2.9	−2.4	−3.0	−2.4
Mean per cent change from baseline	−38.2	−48.6	−43.2	−67.9	−70.2	−80.0	−75.6	−83.6	−73.4
Median per cent change from baseline§	−66.7	−79.3	−75.0	−100.0	−100.0	−100.0	−100.0	−100.0	−100.0
Dactylitis count of 0¶, n/m (%)	80/205 (39.0)	102/221 (46.2)	95/207 (45.9)	168/249 (67.5)	150/225 (66.7)	155/200 (77.5)	132/182 (72.5)	144/181 (79.6)	116/157 (73.9)

*The n at week 24 represents patients with a baseline value >0 and ≥1 postbaseline value at or before week 24. Data as observed for weeks 52, 104 and 156. The n represents the number of patients taking apremilast, regardless of when treatment started (baseline, week 16 or week 24), with a baseline value >0 and a value at the specific visit.

†Dactylitis count is the sum of all scores for each of the 20 digits, with each digit scored as 0=absence or 1=presence of dactylitis.

‡P<0.01 vs placebo.

§The per cent change noted occurred in >50% of patients.

¶Patients who did not have sufficient data (observed or imputed) for a definitive determination of response status at week 24 are counted as non-responders.

LOCF, last observation carried forward.